SENORES — Senores Pharmaceuticals Share Price
Last trade - 00:00- IN₹23.66bn
- IN₹26.24bn
- IN₹2.15bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.66 | ||
| Price to Tang. Book | 11.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.1 | ||
| EV to EBITDA | 63.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.44% | ||
| Return on Equity | 15.4% | ||
| Operating Margin | 14.73% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | n/a | 141.7 | 353.37 | 2,145.24 | n/a | n/a | 289.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +761.98 | +268.5 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Senores Pharmaceuticals Limited is an India-based pharmaceutical company. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. It supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- January 1st, 1970
- Incorporated
- December 26th, 2017
- Public Since
- December 30th, 2024
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 46,053,588
- Address
- AHMEDABAD, 380054
- Web
- https://senorespharma.com/
- Phone
- +91 7929999857
- Auditors
- Pankaj K. Shah Associates
Similar to SENORES
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 23:09 UTC, shares in Senores Pharmaceuticals are trading at IN₹517.05. This share price information is delayed by 15 minutes.
Shares in Senores Pharmaceuticals last closed at IN₹517.05 and the price had moved by over the past 365 days. In terms of relative price strength the Senores Pharmaceuticals share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreSenores Pharmaceuticals does not currently pay a dividend.
Senores Pharmaceuticals does not currently pay a dividend.
Senores Pharmaceuticals does not currently pay a dividend.
To buy shares in Senores Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹517.05, shares in Senores Pharmaceuticals had a market capitalisation of IN₹23.66bn.
Here are the trading details for Senores Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SENORES
Based on an overall assessment of its quality, value and momentum Senores Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Senores Pharmaceuticals. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹517.05, shares in Senores Pharmaceuticals were trading -5.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Senores Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹517.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Senores Pharmaceuticals' directors